Drug Profile
Research programme: anticancer monoclonal antibodies - Pierre Fabre/AbbVie
Alternative Names: 515H7; Mab 515H7Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Class Monoclonal antibodies
- Mechanism of Action Platelet factor 4 inhibitors; Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in France (IV, Injection)
- 01 Feb 2010 Pierre Fabre and Abbott Canada enter into an exclusive worldwide licensing agreement
- 19 Nov 2009 Pharmacodynamics data from a preclinical trial in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)